Answer
In efavirenz/emtricitabine/tenofovir disoproxil, efavirenz inhibits HIV-1 reverse transcriptase non-competitively, while emtricitabine and tenofovir, formed from tenofovir disoproxil, undergo cellular phosphorylation to emtricitabine triphosphate and tenofovir diphosphate, which competitively inhibit the enzyme, causing DNA chain termination.
Sources for this answer
- Efavirenz/Emtricitabine/Tenofovir disoproxil Dr. Reddy's 600 mg/200 mg/245 mg Film-Coated TabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated
Sources checked